Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 06, 2026 16:12 ET | Source: Alumis Inc.

Alumis Announces Proposed Public Offering of Common Stock

Alumis Announces Proposed Public Offering of Common Stock
January 06, 2026 07:00 ET | Source: Alumis Inc.

Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
January 05, 2026 17:00 ET | Source: Alumis Inc.

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis on Jan 6, 2026
November 13, 2025 16:15 ET | Source: Alumis Inc.

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Alumis reports third quarter 2025 financial results and highlights recent progress and anticipated milestones including Phase 3 data in early 1Q 2026
November 04, 2025 08:00 ET | Source: Alumis Inc.

Alumis to Participate in Upcoming November Investor Conferences

Alumis to participate in two upcoming November investor conferences: Guggenheim’s 2nd Annual Healthcare Innovation Conf and the Stifel 2025 Healthcare Conf
August 29, 2025 07:00 ET | Source: Alumis Inc.

Alumis to Participate in Upcoming September Investor Conferences

Alumis management will participate in several healthcare conference upcoming in September
August 13, 2025 16:05 ET | Source: Alumis Inc.

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update
July 24, 2025 07:30 ET | Source: Alumis Inc.

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

Alumis Completes Patient Enrollment in Global LUMUS Phase 2b Trial of ESK-001, Next-Generation Oral TYK2 Inhibitor for SLE, data in 3Q 2026
July 14, 2025 16:05 ET | Source: Alumis Inc.

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary
May 29, 2025 16:15 ET | Source: Alumis Inc.

Alumis to Present at the Jefferies Global Healthcare Investor Conference

Alumis to present at Jefferies Global Healthcare Conference on June 4, 2025